Cost-effectiveness of Low-Dose Computed Tomography With a Plasma-Based Biomarker for Lung Cancer Screening in China

Article Oncology

Cost Effectiveness of Lung Cancer Screening With Low-Dose CT in Heavy Smokers in China

Jingmin Yuan et al.

Summary: This study provides the optimal lung cancer screening strategy in China based on cost-effectiveness analysis. The results suggest that starting screening at 50 years old can achieve the maximum net health benefits for heavy smokers.

CANCER PREVENTION RESEARCH (2022)

Add to Collection

Article Critical Care Medicine

One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study

Ni Li et al.

Summary: This study evaluated the effectiveness of one-off low-dose CT (LDCT) screening for the early detection of lung cancer in China. The results showed that one-off LDCT screening significantly reduced lung cancer mortality and all-cause mortality, indicating its potential in countries with limited medical resources.

LANCET RESPIRATORY MEDICINE (2022)

Add to Collection

Article Oncology

Cost-Effectiveness of Smoking Cessation Interventions in the Lung Cancer Screening Setting: A Simulation Study

Christopher J. Cadham et al.

Summary: This study compared the benefits and costs of different smoking cessation interventions in the context of lung cancer screening. The results showed that all cessation interventions reduced cases of and deaths from lung cancer. Efficient cessation strategies included pharmacotherapy combined with web-based, telephone, or individual counseling, with costs per QALY well below accepted thresholds.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)

Add to Collection

Article Oncology

Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening

Iakovos Toumazis et al.

Summary: The study found that the 2021 USPSTF recommendation for lung cancer screening was cost-effective compared to the 2013 recommendation, but expanding screening eligibility to include former smokers who have quit for more than 15 years may further improve cost-effectiveness. Alternative screening strategies with a minimum cumulative smoking exposure of 20 pack-years, including individuals who quit within the past 25 years, were found to be more cost-effective than the 2021 recommendation.

JAMA ONCOLOGY (2021)

Add to Collection

Article Oncology

Preferred Lung Cancer Screening Modalities in China: A Discrete Choice Experiment

Zixuan Zhao et al.

Summary: Limited results on public attitudes towards lung cancer screening exist in both China and abroad. This study aimed to identify preferred screening modalities in a Chinese population and predict uptake rates of different modalities. Findings suggested that screening interval, screening venue, and out-of-pocket costs significantly influenced preferences, with a preference towards LDCT + blood test annually at a cost of RMB 50. Those without endowment insurance were more likely to opt out, suggesting a need for financial support to reduce attendance inequalities among disadvantaged elderly individuals.

CANCERS (2021)

Add to Collection

Article Oncology

Performance of the EarlyCDT® Lung test in detection of lung cancer and pulmonary metastases in a high-risk cohort

Morten Borg et al.

Summary: Early detection of lung cancer is crucial for a better prognosis, but the blood-based biomarker test showed insufficient sensitivity, particularly in early-stage patients, for inclusion in a low-dose CT screening program.

LUNG CANCER (2021)

Add to Collection

Article Medicine, General & Internal

Determining cost-effectiveness of lung cancer screening in urban Chinese populations using a state-transition Markov model

Chengyao Sun et al.

Summary: This study examines the cost-effectiveness of annual low-dose CT (LDCT) screening for high-risk cancer populations in Chinese urban areas. Using a Markov model, the study found that an initial screening age of 55 years is the most cost-effective strategy. Sensitivity, specificity, and the overdiagnosis rate were identified as influencing factors for the cost-effectiveness of LDCT screening.

BMJ OPEN (2021)

Add to Collection

Article Oncology